Developer docs
API playgroundTry for free, no card

Search company profiles

Ascension Ventures

Full company profile

uuid0003j3x

Namestring
Ascension Ventures
Legal namestring
Ascension Ventures
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ascension Ventures is a strategic healthcare venture fund and early-stage venture capital firm founded in 2001 and headquartered in St. Louis, Missouri. It pioneered the multi-system limited partner investment model in healthcare, aggregating commitments from 13 major nonprofit healthcare systems — including Ascension, AdventHealth, Intermountain Healthcare, Sentara, and Texas Health Resources — that collectively operate 300+ acute care hospitals, employ 453,000 associates, and generate $102 billion in annual revenue across 22 states and Washington, D.C.

The firm invests $10 to $20 million per company, typically taking a board seat or observation rights, and concentrates on early- to late-stage healthcare technology, medical devices/life sciences, and healthcare services companies. Its stated thematic focus areas — "Smarter Technologies, Bigger Data, Better Alternatives, Healthier Futures" — map onto a portfolio exceeding 70 companies spanning kidney care (Strive Health), precision medicine (Syapse), AI-driven diagnostics and process automation (Cofactor Genomics, Olive), patient engagement (Phreesia, GetWellNetwork), medical devices (RefleXion Medical, Cala Health, NextSense), and behavioral health (Mindpath Health, Owl). The firm does not build proprietary technology products; its competitive offering is strategic guidance, network access to LP hospital systems, and diligence informed by clinical and operational experience across its investment team.

Ascension Ventures generates returns primarily through capital appreciation and exits from its portfolio (with multiple historical liquidity events including the BioImagene acquisition by Roche/Ventana, MindFrame by Covidien, SeQual by Chart Industries, and TomoTherapy's IPO and later acquisition by Accuray), supplemented by standard VC management fees on greater than $1 billion in capital under management. The firm deploys a sales-led, referral-driven deal sourcing model — direct outreach from healthcare innovators and networking through LP health systems — and operates a restricted partner portal for LP document distribution.

Short descriptiontext

Ascension Ventures is a strategic healthcare venture capital firm founded in 2001, investing $10-$20M per company on behalf of 13 nonprofit healthcare system LPs that collectively operate 300+ hospitals across 22 states and manage over $1 billion in capital.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, strategic equity investments, medical device funding, healthcare innovation funding, limited partner platform
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeSubscription Recurring
Description

Ascension Ventures operates as a venture capital fund, generating returns through capital appreciation and exits from portfolio companies. The fund has more than $1 billion in capital under management and serves limited partners consisting of major healthcare systems.

ascensionventures.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ascension Ventures is a strategic healthcare venture capital fund that makes equity investments of $10-$20 million per company in early- to late-stage healthcare IT, medical device, and healthcare services companies. With more than $1 billion in capital under management, the firm manages a diversified portfolio companies and serves as a multi-system Limited Partner platform connecting 13+ nonprofit healthcare systems with healthcare innovators. The firm provides portfolio companies with strategic guidance, often requesting board seats or observation rights, and access to a network of 300+ acute care hospitals and 453,000 associates across 22 states.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than $1 billion in capital under management
+2 more records
Product overview1 text field

Ascension Ventures is a strategic healthcare venture fund with over $1 billion in capital under management. The firm does not develop or sell its own technology products; instead, it maintains a diversified portfolio of healthcare companies across healthcare services, medical technology/life sciences, and healthcare IT sectors. The portfolio includes companies focused on telemedicine platforms (Zipnosis), AI/healthcare automation (Olive, Censys), precision medicine (Syapse, Cofactor Genomics), medical devices (RefleXion Medical, Cala Health, NextSense), patient engagement (GetWellNetwork, Phreesia), diagnostics (Bardy Diagnostics, HealthMyne), kidney care (Strive Health), behavioral health (Owl, Mindpath Health), and various other healthcare technology and service offerings. The fund serves as a strategic investment vehicle for healthcare systems seeking to participate in healthcare innovation.

Product and service2 records
1Partner Portal
CategoryCore Platform
2Strategic Healthcare Venture Capital Fund
CategoryVenture Capital Fund
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Healthcare-dedicated investment firm across private equity, venture, and royalty/credit; broader incumbent with deeper healthcare specialization across stages, partially overlapping medtech and healthcare services focus.

TypeDirect peer
Description

Strategic healthcare venture capital platform backed by multiple health systems, with a similar multi-LP structure and focus on early- to growth-stage healthcare investments; directly comparable as a strategic healthcare-system-affiliated investor.

TypeDirect peer
Description

Venture capital arm of Providence Health system making strategic healthcare investments; highly comparable as a single-system-affiliated strategic healthcare VC with similar investment criteria and value-add through clinical validation.

TypeDirect peer
Description

Wisconsin-based early-stage digital health venture capital firm focused on healthcare technology; directly comparable as a healthcare-focused early-stage VC where AV's Taha Jangda was previously a General Partner.

TypeDirect peer
Description

Boston-based early-stage venture capital firm with a dedicated healthcare practice investing in healthcare IT, services, and medical devices; comparable in stage, check size, and healthcare focus.

TypeDirect peer
Description

Strategic venture capital arm of Kaiser Permanente, one of the largest US nonprofit health systems; directly comparable as a health-system-affiliated strategic investor in early- to growth-stage healthcare companies.

TypeBroad incumbent
Description

Venture capital arm of Optum/UnitedHealth Group making strategic healthcare technology investments at scale; broader incumbent with much larger AUM and capacity, but overlapping thesis in digital health, value-based care, and healthcare AI.

TypeBroad incumbent
Description

Large multi-stage venture firm with a dedicated Health Assurance thesis and health system partnerships; broader incumbent with greater scale and longer fund vintages, but overlapping healthcare mandate and investor model.

TypeBroad incumbent
Description

Major venture firm with dedicated bio/healthcare funds investing across healthcare services, digital health, and life sciences; broader incumbent with deeper capital base, overlapping investment categories though generally at different stages.

TypeDirect peer
Description

Innovation and venture arm of Memorial Hermann Health System making strategic investments in healthcare technology companies; directly comparable as a single-system-affiliated strategic healthcare investor with similar model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment108 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ascension Ventures

Healthcare Venture Capitalascensionventures.org

Ascension Ventures is a strategic healthcare venture capital firm founded in 2001, investing $10-$20M per company on behalf of 13 nonprofit healthcare system LPs that collectively operate 300+ hospitals across 22 states and manage over $1 billion in capital.

What Ascension Ventures does

Ascension Ventures is a strategic healthcare venture fund and early-stage venture capital firm founded in 2001 and headquartered in St. Louis, Missouri. It pioneered the multi-system limited partner investment model in healthcare, aggregating commitments from 13 major nonprofit healthcare systems — including Ascension, AdventHealth, Intermountain Healthcare, Sentara, and Texas Health Resources — that collectively operate 300+ acute care hospitals, employ 453,000 associates, and generate $102 billion in annual revenue across 22 states and Washington, D.C.

The firm invests $10 to $20 million per company, typically taking a board seat or observation rights, and concentrates on early- to late-stage healthcare technology, medical devices/life sciences, and healthcare services companies. Its stated thematic focus areas — "Smarter Technologies, Bigger Data, Better Alternatives, Healthier Futures" — map onto a portfolio exceeding 70 companies spanning kidney care (Strive Health), precision medicine (Syapse), AI-driven diagnostics and process automation (Cofactor Genomics, Olive), patient engagement (Phreesia, GetWellNetwork), medical devices (RefleXion Medical, Cala Health, NextSense), and behavioral health (Mindpath Health, Owl). The firm does not build proprietary technology products; its competitive offering is strategic guidance, network access to LP hospital systems, and diligence informed by clinical and operational experience across its investment team.

Ascension Ventures generates returns primarily through capital appreciation and exits from its portfolio (with multiple historical liquidity events including the BioImagene acquisition by Roche/Ventana, MindFrame by Covidien, SeQual by Chart Industries, and TomoTherapy's IPO and later acquisition by Accuray), supplemented by standard VC management fees on greater than $1 billion in capital under management. The firm deploys a sales-led, referral-driven deal sourcing model — direct outreach from healthcare innovators and networking through LP health systems — and operates a restricted partner portal for LP document distribution.

Ascension Ventures firmographics

Firmographics
Name
Ascension Ventures
Legal name
Ascension Ventures
Website
https://ascensionventures.org
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Ascension Ventures is a strategic healthcare venture capital firm founded in 2001, investing $10-$20M per company on behalf of 13 nonprofit healthcare system LPs that collectively operate 300+ hospitals across 22 states and manage over $1 billion in capital.
Ownership category
akta.pro rank

Ascension Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Healthcare venture capital
  • Strategic equity investments
  • Medical device funding
  • Healthcare innovation funding
  • Limited partner platform

Where Ascension Ventures is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Ascension Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Fund Management: Ascension Ventures operates as a venture capital fund, generating returns through capital appreciation and exits from portfolio companies. The fund has more than $1 billion in capital under management and serves limited partners consisting of major healthcare systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ascension Ventures product offering

Product offering

Core offering

Ascension Ventures is a strategic healthcare venture capital fund that makes equity investments of $10-$20 million per company in early- to late-stage healthcare IT, medical device, and healthcare services companies. With more than $1 billion in capital under management, the firm manages a diversified portfolio companies and serves as a multi-system Limited Partner platform connecting 13+ nonprofit healthcare systems with healthcare innovators. The firm provides portfolio companies with strategic guidance, often requesting board seats or observation rights, and access to a network of 300+ acute care hospitals and 453,000 associates across 22 states.

Product overview

Ascension Ventures is a strategic healthcare venture fund with over $1 billion in capital under management. The firm does not develop or sell its own technology products; instead, it maintains a diversified portfolio of healthcare companies across healthcare services, medical technology/life sciences, and healthcare IT sectors. The portfolio includes companies focused on telemedicine platforms (Zipnosis), AI/healthcare automation (Olive, Censys), precision medicine (Syapse, Cofactor Genomics), medical devices (RefleXion Medical, Cala Health, NextSense), patient engagement (GetWellNetwork, Phreesia), diagnostics (Bardy Diagnostics, HealthMyne), kidney care (Strive Health), behavioral health (Owl, Mindpath Health), and various other healthcare technology and service offerings. The fund serves as a strategic investment vehicle for healthcare systems seeking to participate in healthcare innovation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Partner Portal
  • Strategic Healthcare Venture Capital Fund

Quantifiable outcome

  • More than $1 billion in capital under management
  • +2 more outcomes

Companies that use Ascension Ventures

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Ascension Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ascension Ventures partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Ascension Ventures competitors and assessment

Company assessment

Broad incumbents

  • OrbiMed: Healthcare-dedicated investment firm across private equity, venture, and royalty/credit; broader incumbent with deeper healthcare specialization across stages, partially overlapping medtech and healthcare services focus.
  • Optum Ventures: Venture capital arm of Optum/UnitedHealth Group making strategic healthcare technology investments at scale; broader incumbent with much larger AUM and capacity, but overlapping thesis in digital health, value-based care, and healthcare AI.
  • General Catalyst (Health Assurance): Large multi-stage venture firm with a dedicated Health Assurance thesis and health system partnerships; broader incumbent with greater scale and longer fund vintages, but overlapping healthcare mandate and investor model.
  • Andreessen Horowitz (Bio + Health Fund): Major venture firm with dedicated bio/healthcare funds investing across healthcare services, digital health, and life sciences; broader incumbent with deeper capital base, overlapping investment categories though generally at different stages.

Direct peers

  • Echo Health Ventures: Strategic healthcare venture capital platform backed by multiple health systems, with a similar multi-LP structure and focus on early- to growth-stage healthcare investments; directly comparable as a strategic healthcare-system-affiliated investor.
  • Providence Ventures: Venture capital arm of Providence Health system making strategic healthcare investments; highly comparable as a single-system-affiliated strategic healthcare VC with similar investment criteria and value-add through clinical validation.
  • HealthX Ventures: Wisconsin-based early-stage digital health venture capital firm focused on healthcare technology; directly comparable as a healthcare-focused early-stage VC where AV's Taha Jangda was previously a General Partner.
  • .406 Ventures: Boston-based early-stage venture capital firm with a dedicated healthcare practice investing in healthcare IT, services, and medical devices; comparable in stage, check size, and healthcare focus.
  • Kaiser Permanente Ventures: Strategic venture capital arm of Kaiser Permanente, one of the largest US nonprofit health systems; directly comparable as a health-system-affiliated strategic investor in early- to growth-stage healthcare companies.
  • Memorial Hermann Innovation: Innovation and venture arm of Memorial Hermann Health System making strategic investments in healthcare technology companies; directly comparable as a single-system-affiliated strategic healthcare investor with similar model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights5 records

Customer concentration

Ascension Ventures social profiles

Digital presence

Ascension Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ascension Ventures leadership team

Management profile

Number of profiles

Profiles12 records

Ascension Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ascension Ventures M&A and investment

M&A and investment

M&A

Investments108 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascension Ventures

What does Ascension Ventures do?

Ascension Ventures is a strategic healthcare venture capital fund that makes equity investments of $10-$20 million per company in early- to late-stage healthcare IT, medical device, and healthcare services companies. With more than $1 billion in capital under management, the firm manages a diversified portfolio companies and serves as a multi-system Limited Partner platform connecting 13+ nonprofit healthcare systems with healthcare innovators. The firm provides portfolio companies with strategic guidance, often requesting board seats or observation rights, and access to a network of 300+ acute care hospitals and 453,000 associates across 22 states.

Is Ascension Ventures a public or private company?

Ascension Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Ascension Ventures founded?

Ascension Ventures was founded in 2015. It employs 11 to 50 people.

Where is Ascension Ventures based?

Ascension Ventures is headquartered in London, United Kingdom, in the Europe region.

How does Ascension Ventures make money?

One revenue line is on record: fund Management.

Who are Ascension Ventures's main competitors?

Broad incumbents on record are OrbiMed, Optum Ventures, General Catalyst (Health Assurance) and Andreessen Horowitz (Bio + Health Fund). Direct peers are Echo Health Ventures, Providence Ventures, HealthX Ventures, .406 Ventures, Kaiser Permanente Ventures and Memorial Hermann Innovation.

Does Ascension Ventures have an API?

No public API is recorded for Ascension Ventures.

What industry is Ascension Ventures in?

Ascension Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmagBristol based Neuronostics raises £3m led by Empirical Ventures and The FSE GroupNeuronostics raised £3m in a seed round co-led by Empirical Ventures and The FSE Group to accelerate clinical rollout of BioEP, its EEG-based digital biomarker platform for suspected epilepsy. The funding, supported by a £400,000 Innovate UK grant, will fund US regulatory work and NHS adoption, with a planned FDA submission in 2026.AInvestHallmark HCS: A $900 Billion Pitch From a $29 Million Private Company - Too Early To CallHallmark Health Care Solutions, a private healthcare software company, has repositioned its Einstein II vendor management platform as "healthcare's first workforce operating system" targeting the estimated $900 billion annual U.S. healthcare labor market, despite generating only approximately $29 million in revenue as of 2023. The company has received funding from growth investors including Summit Partners and Ascension Ventures, but the article argues that the gap between its $900 billion market narrative and its current operating scale remains substantial. The analysis suggests the rebranding reads more as a fundraising narrative than a proven investment thesis, with the company yet to demonstrate the revenue acceleration, gross margins, or retention metrics that would justify such positioning.Venture Capital Access OnlineRejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and LaunchRejoni, Inc. closed a $25 million financing round with new and existing investors. The funds will support manufacturing, market access, and physician engagement for its Juveena hydrogel system, pending FDA approval. The company expects to scale operations and prepare for commercial launch once approved.VentureBeatRejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and LaunchRejoni, Inc. closed a $25 million financing round with new and existing investors. The funds will support manufacturing, market access, and commercial launch of its Juveena hydrogel system, pending FDA approval. The company expects to scale operations and prepare for launch when approved.Business Wire BlogRejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and LaunchRejoni, Inc. closed a $25 million financing round with new and existing investors to accelerate its Juveena hydrogel system toward FDA approval and launch. The company will use the funds to scale manufacturing, invest in market access, and prepare for commercial launch. Juveena is pending FDA approval and not yet available for sale.FinSMEsVoxmind Raises £546.5K in Pre-Seed FundingVoxmind, a London-based voice biometrics and deepfake detection firm, raised £546.5k in pre-seed funding led by Ascension Ventures. The company will use the funds to accelerate commercial sales in financial services, telecoms, and contact centers, and to optimize its AI models for edge deployment. It also plans to achieve ISO 27001 certification within eight months.StartupmagFintech firm Voxmind closes £546k pre seed led by Ascension Ventures with Mark McDermottVoxmind, a London fintech, closed a £546,491 pre-seed round led by Ascension Ventures to commercialize its voice biometrics and deepfake-detection technology. The funding aims to support deployment of an on-device and cloud authentication stack for financial services and telecoms, following Microsoft and AWS withdrawing cloud voice-authentication services.Tech.euVoxmind raises £546k Pre-Seed funding as cloud giants exit voice biometrics marketLondon-based voice biometrics and deepfake detection startup Voxmind has closed a £546,491 pre-seed round led by Ascension Ventures, with participation from angels including Mark McDermott and members of the Cambridge angel network. The funding arrives as Microsoft retired Azure Speaker Recognition in September 2025 and AWS ends support for Voice ID in May 2026, leaving enterprises without a long-term authentication layer as AI voice fraud accelerates. The company has already signed an OEM agreement with a major unified communications hardware provider, embedding its voice biometric SDK into enterprise IP phone hardware, with commercial pipeline spanning US community banking and European telecoms.StartupriseVoxmind Raises £546K Pre-Seed Funding Led By Ascension VenturesVoxmind raised £546,491 in pre-seed funding led by Ascension Ventures. The London startup's phoneme-frequency extraction engine detects deepfake voices with 99.8% accuracy in under three seconds, and it has secured an OEM agreement with a unified communications hardware provider.StartupmagNunaBio raises £6.5m to build UK enzymatic, cell-free synthetic DNA capacityNunaBio raised £6.5m in a growth round led by Northstar Ventures, with participation from HIT Investments, Maven Capital Partners, Ascension Ventures, and Pioneer Group. The funding will scale its enzymatic, cell-free DNA manufacturing platform to increase domestic capacity for high-fidelity synthetic DNA, addressing supply-chain concerns as 80% of global DNA manufacturing is concentrated in one country.